top of page
background.jpg

Unlocking the Potential of Xelcis Bio™

We invite you to learn more about our groundbreaking technology, business model, market potential, and strategic vision. Join us in advancing the future of oncology therapeutics.

SCROLL DOWN

Problems We’re Addressing

Making Chemotherapy Safer and More Effective

Conventional chemotherapy doesn’t just attack cancer—it damages healthy tissue, causing severe side effects that reduce patient quality of life and drive up healthcare costs. At Xelcis Bio™, we’re solving this problem with TRIDENT™—our innovative, pH-responsive delivery platform that targets tumors with precision, aiming to improve outcomes while reducing toxicity.

Lack of Precision

Current chemotherapy agents don't target cancer cells specifically, harming healthy tissues and reducing treatment success.

High Toxicity

Chemotherapy drugs like doxorubicin damage healthy cells, causing severe side effects that limit treatment.

At Xelcis Bio™, we’ve developed the TRIDENT™ platform to address these challenges head-on.

Executive Summary

Revolutionizing Cancer Treatment with Precision and Innovation

Xelcis Bio™ is leading the way in developing next-generation cancer therapeutics with our proprietary TRIDENT™ platform. Our lead program, TRIDENT™ Doxorubicin, aims to address the significant limitations of current doxorubicin therapy, particularly cardiotoxicity, which often restricts treatment duration and effectiveness. By precisely targeting the delivery of doxorubicin to cancer cells, our approach can potentially improve patient outcomes while reducing serious side effects.

  • The global chemotherapy market is valued at over $31 billion and is expected to reach $55 billion by 2028, with growing demand for advanced drug delivery systems.

  • Our TRIDENT™ platform incorporates a proprietary process that enhances therapeutic performance through dual mechanisms. An external biocompatible layer increases our delivery system’s hydrodynamic size and charge, extending circulation time and improving tumor accumulation.

    Proprietary Technology

  • Xelcis Bio™ is developing next-generation targeted cancer therapeutics 
utilizing our proprietary TRIDENT™ delivery platform. Our lead program integrates doxorubicin onto our proprietary nanoparticle delivery system for targeted delivery to tumors to enhance therapeutic efficacy with the goal of reducing side effects.

    Lead Program Focus

  • The company is pursuing an accelerated development timeline through the FDA's 505(b)(2) regulatory pathway for our lead therapeutic candidate, leveraging existing safety and efficacy data for approved chemotherapy drugs.

    Regulatory Strategy
Corporate Presentation

Discover the Future of Targeted Cancer Therapeutics

Xelcis Bio™ is currently advancing TRIDENT™ through key development stages. Be part of an innovative breakthrough in oncology therapeutics.

$31B+

Global Chemotherapy Market

$55B+

 Projected Market Size by 2028

bottom of page